Filter
601
Text search:
FDA
Featured
84
113
Language
Document type
268
168
79
28
24
19
7
3
2
2
1
Countries
30
19
18
17
12
12
10
10
9
8
8
7
7
7
7
6
6
6
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
195
73
21
16
12
8
4
Toolboxes
136
71
56
34
29
28
25
15
13
13
10
9
9
7
6
6
4
4
3
3
2
1
1
Accessed November, 2017
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
A survival guide for clinicans.
3rd edition.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of Tuberculosis Elimination.
The intent of these guidelines is to develop a holistic, coordinated, proactive and technology driven strategy for management of biological disasters through a culture of prevention, mitigation and preparedness to generate a prompt and effective response in the event of an emergency. Th
...
Therapeutics Information and Pharmacovigilance Centre | TIPC
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Division of Global Migration and Quarantine
April 16, 2012
